**Supplementary Material 1.** Clinical interview based on the criteria for diagnosis of Parkinson’s disease-related fatigue [s1].

At the beginning of this clinical interview, two screening questions corresponding to the core features of the PD-related fatigue diagnosis were presented as follows: 1) ‘have you experienced diminished energy levels or increased perception of effort that are disproportionate to attempted activities or general activity level?’; 2) ‘have these symptoms been present for most of the day every day or nearly every day during the previous month?’. If these screening questions were not endorsed, no further questions were asked, and the patient was assumed not to have a fatigue diagnosis. If both screening questions were affirmatively answered, the symptoms from section A (‘patients must have four or more of the symptoms from section A’) as well as criteria in sections B (‘the patient experiences clinically significant distress or impairment in social, occupational, or other important areas of function as a result of fatigue’), C (‘there is evidence from the history and physical examination suggesting fatigue is a consequence of Parkinson’s disease’), and D (‘the symptoms are not primarily a consequence of comorbid psychiatric disorders, sleep disorders, or medical conditions’) were explored. As for the criteria in section D, we excluded from the diagnosis of fatigue the patients suffering from comorbidities commonly related to secondary fatigue, i.e., major depressive episodes ascertained via the Mini International Neuropsychiatric Inventory (MINI) [s2], apathy (self-rated version of Apathy Evaluation Scale ≥ 41 [s3]), sleep disorders (Parkinson’s Disease Sleep Scale Z-score < -2 [s4] and/or Epworth Sleepiness Scale > 10 [s5]) and/or Obstructive Sleep Apnea [s6] as well as heart failure, hypothyroidism, anaemia, or starting a beta-blocker medication; presence of these last conditions was extrapolated from medical records of patients’ reports.

If one of the criteria necessary for the PD-related fatigue diagnosis was not met, the patient was deemed not to have a fatigue diagnosis and assigned to the nf-PD group.
References

s1. Kluger BM, Herlofson K, Chou KL, Lou JS, Goetz CG, Lang AE, Weintraub D, Friedman J. Parkinson's disease-related fatigue: A case definition and recommendations for clinical research. Movement Disord 2016;31:625-631.

s2. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiat 1998;59(Suppl 20):22-33.

s3. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiat Res 1991;38:143-162.

s4. Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R, Pezzela FR, Forbes A, Högl B, Trenkwalder C. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosur Ps 2002;73:629-635.

s5. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-545.

s6. Epstein LJ, Kristo D, Strollo PJ Jr, Friedman N, Malhotra A, Patil SP, Ramar K, Rogers R, Schwab RJ, Weaver EM, Weinstein MD; Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5:263-276.
**Supplementary Material 2.** Comparison between included and study-refusing patients on demographics and clinical features.

| Variable                  | Included patients (n= 241) | Study-refusing patients (n= 67) | F-test/χ² | p-value |
|---------------------------|----------------------------|--------------------------------|-----------|---------|
| **Demographics:**         |                            |                                |           |         |
| Age                       | 65.36 ± 9.36               | 66.76 ± 9.04                   | 1.02      | 0.312   |
| Sex, maleᵃ                | 142 (58.9%)                | 42 (62.7%)                     | 0.30      | 0.578   |
| **Clinical features**     |                            |                                |           |         |
| Disease duration, years   | 3.44 ± 2.91                | 7.85 ± 4.88                    | 85.50     | <0.001  |
| UPDRS-III                 | 24.98 ± 10.60              | 32.94 ± 12.27                  | 27.20     | <0.001  |
| LEDD total (mg/day)       | 472.86 ± 246.10            | 549.95 ± 343.70                | 3.04      | 0.083   |
| LEDD<sub>DA</sub> (mg/day)| 86.55 ± 117.85             | 71.36 ± 102.90                 | 0.58      | 0.445   |
| LEDD<sub>L-DOPA</sub> (mg/day) | 353.52 ± 246.26 | 311.93 ± 139.08               | 1.13      | 0.288   |

Note. Statistically significant differences are shown in **bold**; a, coded as: 0= male, 1= female; b, UPDRS, Unified Parkinson’s Disease Rating Scale; HY, Hoehn and Yahr; LEDD<sub>DA</sub>, Dopamine Agonists Equivalent Daily Dosage; LEDD<sub>L-DOPA</sub>, Levodopa Equivalent Daily Dosage.
**Supplementary Material 3.** Comorbid diseases in 33 patients who were excluded on the basis of section D of PD-related diagnostic criteria.

| Patient | Depression MINI | Apathy AES ≥ 37 | OSA | Sleep disorders PDSS Z-score < -2 | ESS > 10 | Heart failure | Anemia | Hypothyroidism | Beta-blockers |
|---------|-----------------|-----------------|-----|----------------------------------|---------|---------------|--------|----------------|--------------|
| 1       | X               |                 |     |                                  |         |               |        |                | X            |
| 2       |                 |                 |     |                                  |         |               |        |                | X            |
| 3       | X               |                 |     |                                  |         |               |        |                | X            |
| 4       | X               | X               |     |                                  |         |               |        |                | X            |
| 5       |                 |                 |     |                                  | X       |               |        |                | X            |
| 6       | X               |                 |     |                                  |         |               |        |                | X            |
| 7       | X               |                 |     |                                  | X       | X             | X      |                | X            |
| 8       | X               |                 |     |                                  |         |               |        |                | X            |
| 9       |                 |                 |     |                                  |         |               |        |                | X            |
| 10      | X               |                 |     |                                  |         |               |        |                | X            |
| 11      | X               |                 |     |                                  |         |               |        |                | X            |
| 12      | X               |                 |     |                                  |         |               |        |                | X            |
| 13      | X               |                 |     |                                  |         |               |        |                | X            |
| 14      | X               |                 |     |                                  |         |               |        |                | X            |
| 15      |                 |                 |     |                                  |         |               |        |                | X            |
| 16      |                 |                 |     |                                  | X       | X             | X      |                | X            |
| 17      | X               |                 |     |                                  |         |               |        |                | X            |
| 18      | X               |                 |     |                                  |         |               |        |                | X            |
| 19      | X               |                 |     |                                  |         |               |        |                | X            |
| 20      | X               |                 |     |                                  |         |               |        |                | X            |
| 21      | X               |                 |     |                                  | X       | X             | X      |                | X            |
| 22      | X               |                 |     |                                  | X       | X             | X      |                | X            |
| 23      | X               |                 |     |                                  |         |               |        |                | X            |
| 24      |                 |                 |     |                                  |         |               |        |                | X            |
| 25      |                 |                 |     |                                  |         |               |        |                | X            |
| 26      | X               |                 |     |                                  |         |               |        |                | X            |
| 27      | X               |                 |     |                                  | X       | X             | X      |                | X            |
|   | X | X |   |
|---|---|---|---|
| 28 |   |   | X |
| 29 | X |   | X |
| 30 |   | X |   |
| 31 | X |   |   |
| 32 |   | X | X |
| 33 |   |   | X |

Note. MINI, Mini International Neuropsychiatric Inventory; AES, Apathy Evaluation Scale; OSA: Obstructive Sleep Apnea; PDSS, Parkinson’s Disease Sleep Scale; ESS, Epworth Sleepiness Scale.